Pathology of preinvasive and excellent-prognosis breast cancer

Current Opinion in Oncology

Volumn 8, Issue 6, 1996, Pages 462-467

  Page, David L ^a   Simpson, Jean F ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CARCINOMA IN SITU; ECHOGRAPHY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAMMOGRAPHY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEREOTAXIC SURGERY;

EID: 0029853564     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199611000-00004     Document Type: Review

References (41)

1. Poller DN, Ellis IO: Ductal carcinoma in situ (DCIS) of the breast In Progress in Pathology. Edited by Kirkham N, Lemoine NR. Edinburgh: Churchill Livingstone; 1995:47-87.
2. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146-151.
3. Page DL, Salhany KE, Jensen RA, Dupont WD: Subsequent cancer risk after biopsy with atypia in breast papillomas. Cancer 1996, 78:258-266. Although requiring verification, specifically defined atypical hyperplasia within papillomas may indicate a risk for local recurrence.
4. Weinstat-Saslow D, Merino MJ, Manrow RE, et al.: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995, 1:1257-1260.
5. Page DL, Simpson JF: Pathology of preinvasive and excellent prognosis breast cancer. Curr Opin Oncol 1994, 6:549-553.
6. Simpson JF, Page DL: Pathology of preinvasive and excellent prognosis breast cancers. Curr Opin Oncol 1995, 7:501-505.
7. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC: Incidence of and treatment for ductal carcinoma in situ of the breast JAMA 1996, 275:913-918. The recent huge increase in incidence of DCIS is documented. Surprisingly, in 1992, 30% of DCIS lesions in the United States were being treated by surgery alone.
8. Lagios MD, Margolin FR, Westdahl PR, Rose MR: Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63:618-624.
9. Page DL, Jensen RA: Ductal carcinoma in situ of the breast: understanding the misunderstood stepchild. JAMA 1996, 275:948-949.
10. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA: Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995, 76:1197-1200. Small low-grade cases of DCIS not treated by complete excision have about a 30% likelihood of developing into invasive carcinoma. This continued local recurrence is present at the same site as the initial DCIS, supporting a precursor role for DCIS.
11. Page DL, Dupont WD, Rogers LW, Landenberger M: Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982, 49:751-758.
12. Silverstein MJ, Lagios MD, Craig PH, et al.: A prognostic index for ductal carcinoma in situ of the breast Cancer 1996, 77:2267-2274. This is the first of many evolving efforts to provide a predictive index guiding the therapeutic approach to the different forms of DCIS.
13. Schnitt SJ, Harris JR, Smith BL: Developing a prognostic index for ductal carcinoma in situ of the breast: are we there yet? Cancer 1996, 77:2189-2192.
14. Holland R, Peterse JL, Millis RR, et al.: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994, 11:167-180.
15. Scott M, Axelsson K, Lagios M, Anderson T, Rogers L, Page DL: Ductal carcinoma in situ of the breast, reproducibility of histologic subtype analysis. Mod Pathol 1995, B:25A.
16. Bose S, Lesser ML, Norton L, Rosen PP: Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996, 120:81-85.
17. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995, 9:444-450.
18. Winchester DJ, Sahin AA, Tucker SL, Singletary SE: Tubular carcinoma of the breast: predicting axillary nodal metastases and recurrence. Ann Surg 1996, 223:342-347.
19. Marcus JN, Watson P, Page DL, et al.: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77:697-709. The phenotypic correlates of hereditary breast cancer are suggested.
20. Eisinger F, Stoppa-Lyonnet D, Longy M, et al.: Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996, 56:471-474.
21. Pedersen L, Zedeler K, Hoick S, Schiodt T, Mouridsen HT: Medullary carcinoma of the breast Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995, 31A:2289-2295.
22. Rosner D, Lane WW: Predicting recurrence in axillary-lymph node negative breast cancer. Breast Cancer Res Treat 1993, 25:127-139.
23. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RVP: Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (Ta1,b,N0,M0). Cancer 1995, 76:2266-2274. More studies such as this one of the special behavioral correlates of small tumors are needed.
24. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast Histopathology 1982, 6:149-161.
25. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorual T, Durand J-C, Fourquet A, Pouillart P: Infiltrating lobular carcinoma of the breast: clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77:113-120.
26. Schnitt SJ, Connolly JL, Silver B, Harris JR: Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 1989, 64:448-454.
27. du Toit RS, Locker AP, Ellis IO, Nicholson RI, Blarney RW: Invasive lobular carcinomas of the breast: the prognosis of histopathological subtypes. Br J Cancer 1989, 60:605-609.
28. Schnitt SJ, Hayman J, Gelman RS, et al.: A prospective study of conservative surgery alone in the treatment of selected patients with stage 1 breast cancer. Cancer 1996, 77:1094-1100. The usefulness of radiation therapy for most conservatively treated invasive breast cancers is supported.
29. Vetto J, Pommier R, Schmidt W, et al.: Use of the "triple test" for palpable breast lesions yields high diagnostic accuracy and cost savings. Am J Surg 1995, 169:519-522.
30. Stanley MW, Abele J, Frable WJ, Page DL: Letter to the editor. Am J Surg Pathol 1995, 19:483-485.
31. Doyle AJ, Murray KA, Nelson EW, Bragg DG: Selective use of imageguided large-core needle biopsy of the breast: accuracy and cost-effectiveness. AJR Am J Roentgenol 1995, 165:281-284.
32. Liberman L, Dershaw DD, Rosen PP, Cohen MA, Hann LE, Abramson AF: Stereotaxic core biopsy of impalpable spiculated breast masses. AJR Am J Roentgenol 1995, 165:551-554.
33. Montgomery S: Atypical ductal hyperplasia from stereotactic core biopsy of the breast Am J Roentgenol 1996, 166:1230.
34. Dahlstrom JE, Jain S, Sutton T, Sutton S: Diagnostic accuracy of stereotactic core biopsy in a mammographic breast cancer screening programme. Histopathology 1996, 28:421-427.
35. Morrow M: When can stereotactic core biopsy replace excisional biopsy? A clinical perspective. Breast Cancer Res Treat 1995, 36:1-9.
36. Pertschuk LP, Feldman JG, Kim YD, et al.: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma In frozen sections or cytosol-based ligand-binding assays. Cancer 1996, 77:2514-2519. This confirms many other studies of the past 10 years supporting immunohistochemical determination of estrogen and progesterone receptors.
37. Taylor CR: Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer 1996, 77:2419-2422.
38. Van Bogaert L-J: Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. Anal Quant Cytol Histol 1995, 17:75-76.
39. DeMascarel I, Bonichon F, Coindre JM, Trojani M: Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992, 66:523-527.
40. Connolly JL, Fechner RE, Kempson RL, et al.: Recommendations for the reporting of breast carcinoma (ADASP). Am J Clin Pathol 1995, 104:614-619.
41. Henson DE, Fielding P, Grignon DJ, et al.: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: summary. Arch Pathol Lab Med 1995, 119:1109-1112. A consensus of the College of American Pathologists highlights the utility of routinely available measures of prognosis, including predominantly staging and histologic grading.